A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/23/2006	US20060263400 Regulation of mammalian keratinous tissue using skin and/or hair care actives
11/23/2006	US20060263399 Preparation for external use on skin
11/23/2006	US20060263396 Hand lotion and surgical scrub
11/23/2006	US20060263395 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
11/23/2006	US20060263393 Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures
11/23/2006	US20060263392 Method for treating neovascularization
11/23/2006	US20060263385 Composition to relieve side effects of alcohol intoxication
11/23/2006	US20060263383 Prognostic indicator
11/23/2006	US20060263380 IL-12 as an adjuvant for Bordetella pertussis vaccines
11/23/2006	US20060263379 Bordetella pertussis antigen consisting lipopolysaccharide, pertusis toxin, filamentous hemagglutinin, pertactin or abosrbed to alum; interleukin-12 ; enhances cell-mediated immunity in a host
11/23/2006	US20060263376 Pharmaceutical composition comprising PIM-activated NKT cells, and use thereof in therapy
11/23/2006	US20060263373 Utilization of an aminopeptidase inhibitor
11/23/2006	US20060263371 Prognostic indicator
11/23/2006	US20060263370 Prognostic indicator
11/23/2006	US20060263362 Cancer metastasis inhibitor
11/23/2006	US20060263355 Treatment of bone disorders
11/23/2006	US20060263350 Combination antihistamine medication
11/23/2006	US20060263346 Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds
11/23/2006	US20060263343 Molecular dissection of cellular responses to alloantigen or autoantigen in graft rejection and autoimmune disease
11/23/2006	US20060263340 Treating gastrointestinal diseases with modulators of retinoic acid
11/23/2006	US20060263331 Therapeutic use of tumor necrosis factor-alpha mutein
11/23/2006	US20060263330 Antimicrobial polymer compositions and the use thereof
11/23/2006	US20060263329 Antimicrobial polymer compositions and the use thereof
11/23/2006	US20060263328 Hydrophilic polymers with pendant functional groups and method thereof
11/23/2006	US20060263327 Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances
11/23/2006	US20060263323 Invisible antimicrobial glove and hand antiseptic
11/23/2006	US20060263305 Using azithromycin antibiotic
11/23/2006	US20060263301 In situ gelling self-reactive materials for embolization
11/23/2006	US20060263239 Aqueous disinfectants and sterilants including colloidal transition metals
11/23/2006	DE60202452C5 Pyridazinonaldose reductase inhibitoren Reductase inhibitors Pyridazinonaldose
11/23/2006	DE20221679U1 Assembly comprising aqueous solution of oxaliplatin, useful for treating colorectal cancer, in glass bottle having specific volume to surface area ratio for improved stability
11/23/2006	DE20221678U1 Preparation of an oxaliplatin active substance, useful in the treatment of cancer and comprising a very low content of oxalic acid
11/23/2006	DE102006019794A1 Use of glycerylglycosides for stimulating aquaporin expression and in the preparation of cosmetics
11/23/2006	DE102005044814A1 New spiro-isoxazole-cycloalkane compounds, useful as vanilloid receptor 1 ligands for treating e.g. pain, depression and neurodegeneration
11/23/2006	DE102005024012A1 Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln Use of 2,5-disubstituted thiazol-4-one derivatives in medicaments
11/23/2006	DE102005023944A1 Substituierte benzokondensierte Cycloheptanon-Derivate und deren Verwendung zur Herstellung von Arzneimitteln Substituted benzofused cycloheptanone derivatives and their use for the preparation of medicaments
11/23/2006	DE102005023799A1 Wässrige Dispersionen von wasserlöslichen und/oder in Wasser quellbaren anionischen Polymerisaten, Verfahren zu ihrer Herstellung und ihre Verwendung Aqueous dispersions of water-soluble and / or water-swellable anionic polymers, process for their preparation and their use
11/23/2006	DE102005023760A1 Synergistic antiallergic composition, useful for preventing or treating pollen allerginic reactions, comprises a drug combination of acetylsalicylic acid, salmeterol and topical corticosteroid
11/23/2006	DE102005023640A1 Active substance combination, useful for skin moisturizing and stabilization of skin barrier, comprises glucosylglycerides and partially neutralized esters of monoglyceride and/or diglyceride fatty acids with citronic acids
11/23/2006	DE102005023639A1 Active substance combination, useful for skin moisturizing and for stabilizing skin barrier, comprises glucosylglycerides, boundary surface-active glucose derivatives and boundary surface-active oligoglycerine derivatives
11/23/2006	DE102005023636A1 Wirkstoffkombinationen aus Glucosylglyceriden und Kreatin und / oder Kreatinin Active compound combinations of glucosyl glycerides and creatine and / or creatinine
11/23/2006	DE102005023635A1 Active substance combinations, useful for skin moisturizing and in cosmetic preparation, comprises 2,4-bis-((4-(2-ethyl- hexyloxy)-2-hydroxy) -phenyl)-6-(4- methoxyphenyl)- 1,3,5-triazine and glucosylglycerides
11/23/2006	DE102005023207A1 New heteroaryl derivatives are phosphodiesterase-4 enzyme inhibitors useful for the treatment of e.g. respiratory or gastrointestinal complaints or diseases, depression, Alzheimer's disease and Parkinson's disease
11/23/2006	DE102005023170A1 Optimierte Formulierung für mRNA Optimized formulation for mRNA
11/23/2006	DE102005022845A1 Thiobernsteinsäurederivate und deren Verwendung Thiobernsteinsäurederivate and their use
11/23/2006	DE102005022625A1 Verwendung von Taurin zur Steigerung der epidermalen Lipidsynthese Use of taurine to increase epidermal lipid synthesis
11/23/2006	DE102005022020A1 New dibenzocycloheptane compounds are tumor necrosis factor-alpha inhibitors useful to treat e.g. cancer, rheumatic arthritis, gout, septic shock, osteoporosis, naturopathic pain, HIV-propagation and periodontal diseases
11/23/2006	DE102005021963A1 New substituted dihydropyrazolotriazinone compounds, useful for treating bacterial diseases/infections
11/23/2006	DE102005019718A1 New heteroaryl derivatives are phosphodiesterase-4 enzyme inhibitors useful for the treatment of e.g. respiratory or gastrointestinal complaints or diseases, depression, Alzheimer's disease and Parkinson's disease
11/23/2006	DE102004054731A1 New pharmaceutical composition comprising an oligonucleotide that is adapted to target nucleic acids encoding CD40, useful for preventing or treating an inflammatory, immune or autoimmune disorder
11/23/2006	CA2612727A1 Morphine sulfate formulations
11/23/2006	CA2611896A1 Non-peptidic inhibitors of akap/pka interaction
11/23/2006	CA2611506A1 Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
11/23/2006	CA2609900A1 Stilbene derivatives and methods of inhibiting cancer cell growth and microbial growth
11/23/2006	CA2609814A1 Method for amelioration of disease condition induced by mood disorder
11/23/2006	CA2609303A1 Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
11/23/2006	CA2609299A1 Raf inhibitor compounds and methods of use thereof
11/23/2006	CA2609288A1 Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors
11/23/2006	CA2609161A1 Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4
11/23/2006	CA2609117A1 A1 adenosine receptor agonists
11/23/2006	CA2609102A1 Int6 protein involved in hypoxia stress induction and use thereof
11/23/2006	CA2609069A1 Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid
11/23/2006	CA2609067A1 An oligonucleotide or its functional homologue, a composition comprising the same and a method for treating b cell neoplasm
11/23/2006	CA2609062A1 Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm
11/23/2006	CA2609059A1 Methods and compositions for the treatment of pain
11/23/2006	CA2609053A1 Compositions and methods for treatment of eye disorders
11/23/2006	CA2609051A1 A1 adenosine receptor agonists
11/23/2006	CA2609043A1 Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections
11/23/2006	CA2609021A1 Compounds useful for treating neurodegenerative disorders
11/23/2006	CA2609002A1 Use of 2,5-disubstituted thiazol-4-one derivatives in the production of drugs for the treatment of disorders or diseases which are mediated at least partly by vanilloid receptors 1(vr1/trpv1 receptors)
11/23/2006	CA2608977A1 Antifungal agents
11/23/2006	CA2608974A1 Substituted 7,8-dihydro-1h-pyrimido[4,5-b][1,4]diazepin-4-amines are novel kinase inhibitors
11/23/2006	CA2608957A1 Pyrrolidine derivative or salt thereof
11/23/2006	CA2608773A1 Substituted benzo(d)isoxazol-3-yl amine compounds as analgesics
11/23/2006	CA2608766A1 2-amino-4-phenylquinazoline derivatives and the use thereof as hsp90 modulators
11/23/2006	CA2608747A1 Elastin producing fibroblast formulations and methods of using the same
11/23/2006	CA2608718A1 1, 2, 4-triazole derivatives as vasopressin antagonists
11/23/2006	CA2608713A1 Method for the treatment of sexual dysfunctions due to medical conditions
11/23/2006	CA2608690A1 Stable tablet containing droxidopa
11/23/2006	CA2608627A1 Novel nsaids possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety
11/23/2006	CA2608599A1 Bicyclic derivatives as modulators of ion channels
11/23/2006	CA2608577A1 Confectionery products for the treatment of dry mouth
11/23/2006	CA2608540A1 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
11/23/2006	CA2608539A1 Process for preparing 3.alpha.(.beta.)-7.alpha.(.beta.)-dihydroxy-6.alpha.(.beta.)-alkyl-5.beta.-cholanic acid
11/23/2006	CA2608496A1 Imidazoquinolines as lipid kinase inhibitors
11/23/2006	CA2608493A1 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the .beta.2 adrenergic receptor
11/23/2006	CA2608473A1 Combination therapy
11/23/2006	CA2608468A1 Tri-, tetra-substituted-3-aminopyrrolidine derivative
11/23/2006	CA2608463A1 Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers
11/23/2006	CA2608436A1 Diarylhydantoin compounds and their use in the treatment of hyperproliferative disorders
11/23/2006	CA2608419A1 Substituted n-arylpyrrolidines as selective androgen receptor modulators
11/23/2006	CA2608405A1 Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
11/23/2006	CA2608386A1 Benzo(d)isoxazol-3-yl-amine compounds and their use as vanilloid receptor ligands
11/23/2006	CA2608385A1 Substituted spiro compounds and their use for producing drugs
11/23/2006	CA2608383A1 Pharmaceutical composition comprising an oleaginous ointment and vitamin d or the derivatives thereof in solubilised form
11/23/2006	CA2608363A1 Method for the treatment of drug-induced sexual dysfunction
11/23/2006	CA2608362A1 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
11/23/2006	CA2608361A1 Morphine sulphate formulations
11/23/2006	CA2608333A1 Pyrrolopyridine derivatives as protein kinase inhibitors
11/23/2006	CA2608324A1 Pyrolle derivatives as positive allosteric modulators of metabotropic glutamate receptors

1 ... 3996 3997 3998 3999 4000 4001 4002 4003 4004 4005 4006 4007 4008 4009 4010 4011 4012 4013 4014 4015 4016 ... 7860